Metabolic syndrome in psoriatic arthritis patients: A cross-sectional study

International Journal of Rheumatic Diseases

Volumn 16, Issue 6, 2013, Pages 667-673

  Sharma, Aman ^a   Gopalakrishnan, Dharmesh ^a   Kumar, Ramesh ^a   Vijayvergiya, Rajesh ^a   Dogra, Sunil ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Clinical aspects; Metabolic syndrome; Psoriatic arthritis

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSENSUS; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERTENSION; INDIAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT CARE; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

CLINICAL ASPECTS; METABOLIC SYNDROME; PSORIATIC ARTHRITIS;

ADULT; AGED; ARTHRITIS, PSORIATIC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84891371216     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12134     Document Type: Article

References (56)

1. Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4, 441-7.
2. Sharma A, Dogra S (2010) Management of psoriatic arthritis. Indian J Dermatol Venereol Leprol 76, 645-51.
3. Alamanos Y, Voulgari PV, Drosos AA (2008) Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 35, 1354-8.
4. Grundy SM, Cleeman JI, Daniels SR et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 112, 2735-52.
5. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375, 1415-28.
6. Isomaa B, Almgren P, Tuomi T et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-9.
7. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM (2004) Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes mellitus and/or cardiovascular disease? Diabetes Care 27, 2676-81.
8. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55, 829-35.
9. Wakkee M, Thio HB, Prens EP, Sijbrands EJG, Neumann HAM (2007) Unfavourable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 190, 1-9.
10. Mallbris L, Ritchlin CT, Stahle M (2006) Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8, 355-63.
11. Gisondi P, Girolomoni G (2009) Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr 100 (Suppl 2), 14-21.
12. Azfar RS, Gelfand JM (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20, 416-22.
13. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ (2009) More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 161, 1-7.
14. Boehncke WH, Boehncke S (2008) Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms and clinical consequences. G Ital Dermatol Venereol 143, 307-13.
15. Papo D, Hein R, Ring J (2010) Psoriasis is an independent risk factor for coronary artery disease. Dtsch Med Wochenschr 135, 1749-54.
16. Gottlieb AB, Dann F (2009) Comorbidities in patients with psoriasis. Am J Med 122, 1150.
17. Gisondi P, Tessari G, Conti A et al. (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157, 68-73.
18. Setty AR, Curhan G, Choi HK (2007) Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Ann Intern Med 167, 1670-5.
19. Jabbari A, Johnson-Huang LM, Krueger JG (2011) Role of the immune system and immunological circuits in psoriasis. G Ital Dermatol Venereol 146, 17-30.
20. Hevener AL, Febbraio MA (2010) The 2009 Stock conference report: inflammation, obesity and metabolic disease. Obes Rev 11, 635-44.
21. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12, 204-12.
22. Hansson GK (2009) Atherosclerosis - an immune disease: the Anitschkov lecture 2007. Atherosclerosis 202, 2-10.
23. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaushuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8, 331-4.
24. Kimhi O, Caspi D, Bornstein NM et al. (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36, 203-9.
25. Taylor WJ, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: new criteria from a large international study. Arthritis Rheum 54, 2665-73.
26. Schmitt J, Wozel G (2005) The Psoriasis Area and Severity Index (PASI) is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210, 194-9.
27. Taylor WJ, Harrison AA (2004) Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Care Res 51, 311-15.
28. Mrowietz U, Kragballe K, Reich K et al. (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303, 1-10.
29. Braun J, Pham T, Sieper J, Davis J, Linden SV, Dougados M (2003) International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62, 817-24.
30. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-97.
31. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association (2004) Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109, 551-6.
32. Mishra A, Chowbey P, Makkar BM et al. (2009) Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 57, 163-7.
33. Heng D, Ma S, Lee JJM, Tai BC et al. (2006) Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 186, 367-73.
34. Tan CE, Ma S, Wai D, Chew SK, Tai ES (2004) Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27, 1182-6.
35. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23, 469-80.
36. Nikpour M, Urowitz MB, Gladman DD (2009) Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep 11, 248-54.
37. Sherer Y, Zinger H, Shoenfeld Y (2010) Atherosclerosis in systemic lupus erythematosus. Autoimmunity 43, 98-102.
38. Chung CP, Oeser A, Raggi P et al. (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52, 3045-53.
39. Goodson N (2002) Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14, 115-20.
40. Warrington KJ, Kent PD, Frye RL (2005) Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case-control study. Arthritis Res Ther 7, R984-91.
41. Turiel M, Sitia S, Atzeni F et al. (2010) The heart in rheumatoid arthritis. Autoimmun Rev 9, 414-18.
42. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Brij M (2006) Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15, 675-82.
43. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic Syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 111, 1448-54.
44. Murdolo G, Smith U (2006) The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis 16 (Suppl 1), S35-8.
45. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD (2005) Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 7, 1-24.
46. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44, 2737-45.
47. Spiegelman BM, Flier JS (1996) Adipogenesis and obesity: rounding out the big picture. Cell 87, 377-89.
48. Johnson A, Arnadottir S, Gudjonsson JE et al. (2008) Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 159, 342-50.
49. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116, 1793-801.
50. Hotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 (Suppl 3), S53-5.
51. Spah F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159 (Suppl 2), 10-17.
52. Chung CP, Avalos I, Raggi P, Stein CM (2007) Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 26, 1228-33.
53. Christophers E (2001) Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 26, 314-20.
54. Cohen AD, Gilutz H, Henkin Y et al. (2007) Psoriasis and the metabolic syndrome. Acta Dermatol Venereol 87, 506-9.
55. Ravikiran M, Bhansali A, Ravikumar P et al. (2010) Prevalence and risk factors of metabolic syndrome among Asian Indians: a community survey. Diabetes Res Clin Pract 89, 181-8.
56. Ramachandran A, Snehalata C, Satyavani K, Sivasankari S, Vijay V (2003) Metabolic syndrome in urban Asian Indian adults: a population study using modified ATP III criteria. Diabetes Res Clin Pract 60, 199-204.